Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia

Atherosclerosis

Volumn 230, Issue 1, 2013, Pages 52-60

  Teramoto, Tamio ^a   Shirakawa, Masayoshi ^b   Kikuchi, Masashi ^b   Nakagomi, Mariko ^b   Tamura, Satoko ^b   Surks, Howard K ^c   McCrary Sisk, Christine ^c   Numaguchi, Hirotaka ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Merck Sharp Dohm Res Labs Japan   (Japan)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anacetrapib; Cholesteryl ester transfer protein inhibitor; Dyslipidemia; High density lipoprotein cholesterol

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; C REACTIVE PROTEIN; ELECTROLYTE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TURBIDIMETRY;

ANACETRAPIB; CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR; DYSLIPIDEMIA; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; JAPAN; MALE; MIDDLE AGED; OXAZOLIDINONES; PATIENT SAFETY; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881591770     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.05.012     Document Type: Article

References (33)

1. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Finding in 356,222 primary screens of the Multiple Risk Factor Intervention Trial (MRFIT). JAm Med Assoc 1986, 256:2823-2828.
2. Kannel W.H., Castelli W.P., Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med 1979, 90:85-91.
3. Castelli W.P., Abbott R.D., McNamara P.M. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983, 67:730-734.
4. Knopp R. Drug treatment of lipid disorders. NEngl J Med 1999, 341:498-511.
5. Tall A.R. Plasma cholesteryl ester transfer protein. JLipid Res 1993, 34:1255-1274.
6. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. NEngl J Med 2004, 350:1505-1515.
7. Stein E.A., Roth E.M., Rhyne J.M., Burgess T., Kallend D., Robinson J.G. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010, 31:480-488.
8. Bloomfield D., Carlson G.L., Sapre A., et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and co-administered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157:352-360.
9. Cannon C.P., Shah S., Dansky H.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. NEngl J Med 2010, 363:2406-2415.
10. Krauss R., Wojnooski K., Orr J., et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. JLipid Res 2012, 53:540-547.
11. Davidson M.H., McKenney J.M., Shear C.L., Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. JAm Coll Cardiol 2006, 48:1774-1781.
12. McKenney J.M., Davidson M.H., Shear C.L., Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. JAm Coll Cardiol 2006, 48:1782-1790.
13. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. NEngl J Med 2007, 357:2109-2122.
14. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. NEngl J Med 2007, 356:1620-1630.
15. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. NEngl J Med 2007, 356:1304-1316.
16. Bots M.L., Visseren F.L., Evans G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153-160.
17. F. Hoffmann-La Roche Ltd. Roche provides update on Phase III study of dalcetrapib. [Press release]. Published May 7, 2012 [accessed 27.11.12]. http://www.roche.com/media/media_releases/med-cor-2012-05-07.htm.
18. Hooper A.J., Burnett J.R. Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opin Investig Drugs 2012, 21:1427-1432.
19. Krishna R., Anderson M.S., Bergman A.J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370:1907-1914.
20. Hooper A.J., Burnett J.R. Anacetrapib, a cholesteryl ester transfer protein modulator. Expert Opin Investig Drugs 2012, 21:103-109.
21. Teramoto T., Sasaki J., Ueshima H., et al. Risk factors of atherosclerotic diseases. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. JAtheroscler Thromb 2007, 14:45-50.
22. Fridewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterols in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999, 45:2136-2141.
24. Krishna R., Bergman A.J., Jin B., et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008, 84:679-683.
25. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary artery disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082-1085.
26. Ariyo A.A., Thach C., Tracy R., for the Cardiovascular Health Study Investigators Lp(a) lipoprotein, vascular disease, and mortality in the elderly. NEngl J Med 2003, 349:2108-2115.
27. Davidson M., Liu S.X., Barter P., et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res 2013, 54:467-472.
28. Benn M., Nordestgaard B.G., Jensen G.B., Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:661-670.
29. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAm Med Assoc 2009, 302:1993-2000.
30. Nicholls S.J., Brewer H.B., Kastelein J.J.P., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAm Med Assoc 2011, 306:2099-2109.
31. Temple R. Government viewpoint of clinical trials of cardiovascular drugs. Med Clin North Am 1989, 73:495-509.
32. Dansky H.M., Bloomfield D., Gibbons P., et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. Am Heart J 2011, 162:708-716.
33. REVEAL Study Web site. , [accessed 28.11.12]. http://www.revealtrial.org.